291 related articles for article (PubMed ID: 34768647)
1. Updates on Molecular and Biochemical Development and Progression of Prostate Cancer.
Fahmy O; Alhakamy NA; Rizg WY; Bagalagel A; Alamoudi AJ; Aldawsari HM; Khateb AM; Eldakhakhny BM; Fahmy UA; Abdulaal WH; Fresta CG; Caruso G
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768647
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development.
Bahmad HF; Jalloul M; Azar J; Moubarak MM; Samad TA; Mukherji D; Al-Sayegh M; Abou-Kheir W
Front Genet; 2021; 12():652747. PubMed ID: 33841508
[TBL] [Abstract][Full Text] [Related]
6. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature.
Sood A; Kishan AU; Evans CP; Feng FY; Morgan TM; Murphy DG; Padhani AR; Pinto P; Van der Poel HG; Tilki D; Briganti A; Abdollah F
Eur Urol Oncol; 2024 Feb; 7(1):27-43. PubMed ID: 37423774
[TBL] [Abstract][Full Text] [Related]
8. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer.
Shore ND; Morgans AK; Ryan CJ
Clin Genitourin Cancer; 2021 Jun; 19(3):199-207. PubMed ID: 33129718
[TBL] [Abstract][Full Text] [Related]
9. Androgen Receptor-Related Non-coding RNAs in Prostate Cancer.
Yang Y; Liu KY; Liu Q; Cao Q
Front Cell Dev Biol; 2021; 9():660853. PubMed ID: 33869227
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth.
Luo J; Wang D; Wan X; Xu Y; Lu Y; Kong Z; Li D; Gu W; Wang C; Li Y; Ji C; Gu S; Xu Y
Onco Targets Ther; 2020; 13():9257-9267. PubMed ID: 32982312
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications.
Sheehan B; Guo C; Neeb A; Paschalis A; Sandhu S; de Bono JS
Eur Urol Focus; 2022 Sep; 8(5):1157-1168. PubMed ID: 34167925
[TBL] [Abstract][Full Text] [Related]
12. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
[TBL] [Abstract][Full Text] [Related]
13. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
14. Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer.
Zou Y; Tang F; Talbert JC; Ng CM
PLoS One; 2020; 15(3):e0230571. PubMed ID: 32208461
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer.
Ehsani M; David FO; Baniahmad A
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810413
[TBL] [Abstract][Full Text] [Related]
16. Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study.
Pumpalova YS; Ramakrishnan A; May M; Pentz A; Minkowitz S; Doherty S; Singh E; Chen WC; Rebbeck TR; Neugut AI; Joffe M
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38158645
[TBL] [Abstract][Full Text] [Related]
17. Anti-Cancer Stem-Cell-Targeted Therapies in Prostate Cancer.
Gogola S; Rejzer M; Bahmad HF; Alloush F; Omarzai Y; Poppiti R
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900412
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer.
Wu PY; Lin YC; Huang YL; Chen WM; Chen CC; Lee H
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30384405
[TBL] [Abstract][Full Text] [Related]
19. Comparative pathology of dog and human prostate cancer.
Ryman-Tubb T; Lothion-Roy JH; Metzler VM; Harris AE; Robinson BD; Rizvanov AA; Jeyapalan JN; James VH; England G; Rutland CS; Persson JL; Kenner L; Rubin MA; Mongan NP; de Brot S
Vet Med Sci; 2022 Jan; 8(1):110-120. PubMed ID: 34628719
[TBL] [Abstract][Full Text] [Related]
20. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
